Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM-1: Vyjuvek in Dystrophic Epidermolysis Bullosa
NCT03536143Phase 2Completed
- Sponsor
- Krystal Biotech, Inc.
- Start
- May 2018
- Primary completion
- Nov 2019
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of beremagene geperpavec in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Krystal Biotech, Inc.. Started May 2018; status: completed.
02
Drugs
beremagene geperpavec
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT03536143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536143.